T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
Table 2
Prevalence values of the various T-cell subsets in the examined patient groups and controls.
CD4
CD4/CD45RA
CD4/CD45RO
CD4/CD69
CD4/HLADR
CD4/CD25
CD8
CD8/CD45RA
CD8/CD45RO
CD8/HLADR
CD8/CD69
Th1
Th2
Th17
Treg
Anti-TNF responders
Median
25.90
3.37
47.15
1.63
7.18
1.16
10.70
5.69
12.85
6.02
0.95
21.00
8.03
2.81
5.89
25% percentile
17.43
1.54
20.68
0.46
4.44
0.56
5.39
2.27
5.173
2.63
0.46
16.70
7.14
2.25
4.34
75% percentile
33.93
8.46
63.85
2.845
9.62
1.52
19.30
22.00
17.00
9.74
2.15
23.78
9.35
3.26
6.85
Anti-TNF nonresponders
Median
40.8a
4.13
53.90
1.31
4.33a
1.71
12.80
7.18
9.480
4.10
1.27
18.40
8.19
3.29
5.80
25% percentile
24.50
2.55
22.10
1.07
2.39
1.09
6.00
2.08
3.550
1.20
0.59
6.90
6.740
1.41
4.64
75% percentile
44.90
14.00
62.50
2.70
6.91
6.39
24.70
35.20
15.40
5.41
2.01
21.60
11.20
4.40
7.21
aIL-6R responders
Median
35.4a
3.02
40.00
4.14a,b
5.35
4.38a
5.71a,b
4.96
10.70
2.88
4.47a,b
5.48a,b
12.50a
5.01a,b
4.75
25% percentile
26.6
1.52
8.620
1.46
3.32
1.50
4.00
2.01
7.370
1.64
2.25
3.04
8.540
3.95
4.08
75% percentile
47.30
8.37
52.80
8.10
7.16
5.35
8.12
37.70
14.80
5.19
11.50
16.00
14.40
5.87
5.65
Newly diagnosed untreated RA patients
Median
43.9a
46.55a,b,c
48.60
2.72
3.47a
4.57a
12.40c
64.80a,b,c
28.25a,b,c
2.77
2.59a,b
12.15a
9.25
1.76c
3.14a,b,c
25% percentile
37.05
34.90
37.25
2.36
2.97
3.19
9.78
57.48
21.05
1.84
1.77
10.20
8.84
1.61
2.81
75% percentile
62.03
54.23
61.63
3.51
4.58
4.86
20.05
74.33
34.15
3.98
3.38
14.70
11.00
1.98
3.66
Healthy controls
Median
41.55a
52.65a,b,c
41.55
2.4
2.80a,c
7.13a,b,c,d
19.64a,b,c
69.20a,b,c
23.65a,b,c
2.3a
1.88c
10.75a
5.79a,b,c,d
1.04a,b,c
5.17d
25% percentile
37.5
49.15
35.875
1.84
2.47
6.14
15.72
59.77
15.8
1.65
1.37
9.22
4.85
0.78
4.44
75% percentile
43.65
62.638
49.4
2.85
3.88
7.79
24.12
75.77
28.2
2.92
3.08
12.37
7.09
1.19
5.91
Numbers indicate the median percentages and 25% and 75% percentile values within the whole T-cell population (CD4 and CD8 cells), or within CD4 cells (Th1, Th2, Th17, Treg, and ratios), or for the other markers within the CD4 or CD8 cells, as indicated. a versus anti-TNF responder, b versus anti-TNF nonresponder, c versus anti-IL-6 receptor responder, d versus newly diagnosed untreated RA patients. TNF: tumor necrosis factor alpha; IL-6R: interleukin-6 receptor.
